back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2019-11-29 17:14 Tx date 2019-11-14 |
$PVOT
Pivot Pharmaceuticals Inc. |
Lucky, Chris S.
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
46 - Compensation for services
|
+250,000 vol |
250,000 | |
| Filed 2019-11-29 17:12 Tx date 2019-07-02 |
$PVOT
Pivot Pharmaceuticals Inc. |
Lucky, Chris S.
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-11-29 17:10 Tx date 2019-07-02 |
$PVOT
Pivot Pharmaceuticals Inc. |
Lucky, Chris S.
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$97,500
+250,000 vol $0.39 each |
250,000 | |
| Filed 2019-11-29 17:09 Tx date 2019-07-02 |
$PVOT
Pivot Pharmaceuticals Inc. |
Lucky, Chris S.
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-11-22 09:40 Tx date 2019-10-01 |
$PVOT
Pivot Pharmaceuticals Inc. |
Starr, James Russell Nelles
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
750,000 | ||
| Filed 2019-11-22 09:39 Tx date 2019-11-20 |
$PVOT
Pivot Pharmaceuticals Inc. |
Starr, James Russell Nelles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
+1,500,000 vol |
3,000,000 | |
| Filed 2019-11-22 09:36 Tx date 2019-11-22 |
$PVOT
Pivot Pharmaceuticals Inc. |
Starr, James Russell Nelles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,800
+20,000 vol $0.14 each |
1,517,500 | |
| Filed 2019-11-20 11:14 Tx date 2019-11-20 |
$PVOT
Pivot Pharmaceuticals Inc. |
Starr, James Russell Nelles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,500
+20,000 vol $0.125 each |
1,497,500 | |
| Filed 2019-11-19 19:36 Tx date 2019-09-04 |
$PVOT
Pivot Pharmaceuticals Inc. |
Rinow, Toni
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$267,750
+850,000 vol $0.315 each |
850,000 | |
| Filed 2019-11-19 19:34 Tx date 2019-09-04 |
$PVOT
Pivot Pharmaceuticals Inc. |
Rinow, Toni
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-11-18 11:03 Tx date 2019-11-14 |
$PVOT
Pivot Pharmaceuticals Inc. |
Toth, Krisztian
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+2,500,000 vol |
2,500,000 | |
| Filed 2019-11-18 11:02 Tx date 2019-05-31 |
$PVOT
Pivot Pharmaceuticals Inc. |
Toth, Krisztian
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-11-15 15:23 Tx date 2019-11-12 |
$PVOT
Pivot Pharmaceuticals Inc. |
Renz, Wolfgang
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
+165,000 vol |
365,000 | |
| Filed 2019-11-13 14:58 Tx date 2019-11-13 |
$PVOT
Pivot Pharmaceuticals Inc. |
Starr, James Russell Nelles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,025
+15,000 vol $0.135 each |
1,477,500 | |
| Filed 2019-11-13 06:48 Tx date 2019-11-07 |
$PVOT
Pivot Pharmaceuticals Inc. |
Starr, James Russell Nelles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,175
+15,000 vol $0.145 each |
1,462,500 | |
| Filed 2019-11-12 15:29 Tx date 2019-11-07 |
$PVOT
Pivot Pharmaceuticals Inc. |
Starr, James Russell Nelles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
+15,000 vol |
||
| Filed 2019-11-12 15:29 Tx date 2019-11-07 |
$PVOT
Pivot Pharmaceuticals Inc. |
Starr, James Russell Nelles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
+15,000 vol |
1,462,500 | |
| Filed 2019-10-18 17:04 Tx date 2019-10-16 |
$PVOT
Pivot Pharmaceuticals Inc. |
Ong, Moira Wi Ting
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$925.00
+5,000 vol $0.185 each |
2,347,384 | |
| Filed 2019-10-18 17:03 Tx date 2019-10-16 |
$PVOT
Pivot Pharmaceuticals Inc. |
Ong, Moira Wi Ting
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$9,500
+50,000 vol $0.19 each |
2,342,384 | |
| Filed 2019-10-15 18:56 Tx date 2019-10-15 |
$PVOT
Pivot Pharmaceuticals Inc. |
Starr, James Russell Nelles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
+200,000 vol |
1,447,500 | |
| Filed 2019-10-02 14:50 Tx date 2019-10-02 |
$PVOT
Pivot Pharmaceuticals Inc. |
Starr, James Russell Nelles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$9,800
+40,000 vol $0.245 each |
1,247,500 | |
| Filed 2019-10-01 10:34 Tx date 2019-10-01 |
$PVOT
Pivot Pharmaceuticals Inc. |
Starr, James Russell Nelles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
1,500,000 | ||
| Filed 2019-10-01 10:33 Tx date 2019-10-01 |
$PVOT
Pivot Pharmaceuticals Inc. |
Starr, James Russell Nelles
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
800,000 | ||
| Filed 2019-10-01 10:32 Tx date 2019-10-01 |
$PVOT
Pivot Pharmaceuticals Inc. |
Starr, James Russell Nelles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
1,207,500 | ||
| Filed 2019-07-08 17:27 Tx date 2019-06-06 |
$PVOT
Pivot Pharmaceuticals Inc. |
Kenneth, Kessler Alec
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
5,366,000 | ||
| Filed 2019-07-08 17:27 Tx date 2019-06-06 |
$PVOT
Pivot Pharmaceuticals Inc. |
Kenneth, Kessler Alec
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
5,366,000 | ||
| Filed 2019-06-17 17:48 Tx date 2019-06-12 |
$PVOT
Pivot Pharmaceuticals Inc. |
Toth, Krisztian
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$400,000
+1,000,000 vol $0.40 each |
1,000,000 | |
| Filed 2019-06-17 15:23 Tx date 2019-06-12 |
$PVOT
Pivot Pharmaceuticals Inc. |
Borovsky, Joseph
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$240,000
+600,000 vol $0.40 each |
650,000 | |
| Filed 2019-06-17 15:21 Tx date 2019-06-12 |
$PVOT
Pivot Pharmaceuticals Inc. |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
38 - Redemption, retraction, cancellation, repurchase
|
$-490,000
-700,000 vol $0.70 each |
1,300,000 | |
| Filed 2019-06-14 16:04 Tx date 2019-06-12 |
$PVOT
Pivot Pharmaceuticals Inc. |
Toth, Krisztian
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$40,000
+100,000 vol $0.40 each |
||
| Filed 2019-06-14 16:04 Tx date 2019-06-12 |
$PVOT
Pivot Pharmaceuticals Inc. |
Toth, Krisztian
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$40,000
+100,000 vol $0.40 each |
100,000 | |
| Filed 2019-06-14 15:59 Tx date 2019-05-31 |
$PVOT
Pivot Pharmaceuticals Inc. |
Toth, Krisztian
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-06-07 11:10 Tx date 2019-06-04 |
$PVOT
Pivot Pharmaceuticals Inc. |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
+2,873,562 vol |
20,646,001 | |
| Filed 2019-06-05 15:48 Tx date 2019-05-31 |
$PVOT
Pivot Pharmaceuticals Inc. |
Toth, Krisztian
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
11 - Acquisition or disposition carried out privately
|
+1,049,280 vol |
1,049,280 | |
| Filed 2019-06-05 15:45 Tx date 2019-05-31 |
$PVOT
Pivot Pharmaceuticals Inc. |
Toth, Krisztian
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
11 - Acquisition or disposition carried out privately
|
+1,049,280 vol |
||
| Filed 2019-06-05 15:41 Tx date 2019-05-31 |
$PVOT
Pivot Pharmaceuticals Inc. |
Toth, Krisztian
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-06-05 15:40 Tx date 2019-05-31 |
$PVOT
Pivot Pharmaceuticals Inc. |
Toth, Krisztian
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$262,320
+1,049,280 vol $0.25 each |
1,049,280 | |
| Filed 2019-06-05 15:39 Tx date 2019-05-31 |
$PVOT
Pivot Pharmaceuticals Inc. |
Toth, Krisztian
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-06-05 14:12 Tx date 2018-10-22 |
$PVOT
Pivot Pharmaceuticals Inc. |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+375,000 vol |
375,000 | |
| Filed 2019-06-05 14:10 Tx date 2010-03-18 |
$PVOT
Pivot Pharmaceuticals Inc. |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-06-05 13:04 Tx date 2019-06-03 |
$PVOT
Pivot Pharmaceuticals Inc. |
Frankham, Patrick Charles
4 - Director of Issuer
Holder: Kathleen Caruso (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,760
+8,000 vol $0.47 each |
108,400 | |
| Filed 2019-05-24 16:16 Tx date 2019-05-15 |
$PVOT
Pivot Pharmaceuticals Inc. |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-50,000
-200,000 vol $0.25 each |
17,772,439 | |
| Filed 2019-03-25 Tx date 2015-02-05 |
$PVOT
Pivot Pharmaceuticals Inc. |
Renz, Wolfgang
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-03-25 Tx date 2019-03-25 |
$PVOT
Pivot Pharmaceuticals Inc. |
Ong, Moira Wi Ting
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$30,000
+200,000 vol $0.15 each |
2,292,384 | |
| Filed 2019-03-25 Tx date 2019-03-25 |
$PVOT
Pivot Pharmaceuticals Inc. |
Borovsky, Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$33,677
+290,323 vol $0.116 each |
||
| Filed 2019-03-25 Tx date 2019-03-25 |
$PVOT
Pivot Pharmaceuticals Inc. |
Ong, Moira Wi Ting
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$30,000
+200,000 vol $0.15 each |
||
| Filed 2019-03-25 Tx date 2019-03-25 |
$PVOT
Pivot Pharmaceuticals Inc. |
Borovsky, Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$33,677
+290,323 vol $0.116 each |
575,959 | |
| Filed 2019-03-25 Tx date 2019-03-25 |
$PVOT
Pivot Pharmaceuticals Inc. |
Renz, Wolfgang
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$30,000
+200,000 vol $0.15 each |
200,000 | |
| Filed 2018-11-01 Tx date 2018-10-30 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Sassel Investments Inc. (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
-25,000 vol |
3,239,950 | |
| Filed 2018-11-01 Tx date 2018-03-05 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Sassel Investments Inc. (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
-1,200,000 vol |
||
| Filed 2018-11-01 Tx date 2018-03-02 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Sassel Investments Inc. (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
-1,200,000 vol |
3,264,950 | |
| Filed 2018-11-01 Tx date 2018-03-05 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Sassel Investments Inc. (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
-1,200,000 vol |
||
| Filed 2018-10-27 Tx date 2018-08-27 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Borovsky, Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
285,636 | ||
| Filed 2018-10-27 Tx date 2018-10-22 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$150,000
+375,000 vol $0.40 each |
17,972,439 | |
| Filed 2018-10-26 Tx date 2018-03-31 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Rolfes, Patrick
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
46 - Compensation for services
|
+29,763 vol |
779,763 | |
| Filed 2018-10-26 Tx date 2018-06-06 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Rolfes, Patrick
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
46 - Compensation for services
|
+96,060 vol |
937,470 | |
| Filed 2018-10-26 Tx date 2018-08-27 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Borovsky, Joseph
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
50,000 | ||
| Filed 2018-10-26 Tx date 2018-03-01 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Rolfes, Patrick
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+750,000 vol |
750,000 | |
| Filed 2018-10-26 Tx date 2018-05-03 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Rolfes, Patrick
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
46 - Compensation for services
|
+61,647 vol |
841,410 | |
| Filed 2018-10-26 Tx date 2018-03-01 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Rolfes, Patrick
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-05-21 Tx date 2018-05-15 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$76,440
+136,500 vol $0.56 each |
17,597,439 | |
| Filed 2018-04-17 Tx date 2018-04-10 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Frankham, Patrick Charles
4 - Director of Issuer
Holder: Kathleen Caruso (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$348.00
+400 vol $0.87 each |
100,400 | |
| Filed 2018-04-05 Tx date 2018-04-02 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$54,450
+55,000 vol $0.99 each |
17,460,939 | |
| Filed 2018-04-05 Tx date 2018-04-02 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Khadija Zerouali (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$37,380
+42,000 vol $0.89 each |
284,000 | |
| Filed 2018-03-09 Tx date 2018-03-05 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Sassel Investments Inc. (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
-1,200,000 vol |
3,264,950 | |
| Filed 2018-03-07 Tx date 2010-03-18 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
OTC Puts (including Private Options to Sell) Expiry March 2, 2021
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-03-07 Tx date 2018-03-02 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
OTC Puts (including Private Options to Sell) Expiry March 2, 2021
70 - Acquisition or disposition (writing) of third party derivative
|
$1.40
+2 vol $0.70 each |
2 | |
| Filed 2018-03-05 Tx date 2018-01-23 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Frankham, Patrick Charles
4 - Director of Issuer
Holder: Inflexion Point Healthcare (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
-100,000 vol |
0 | |
| Filed 2018-03-05 Tx date 2018-01-23 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Frankham, Patrick Charles
4 - Director of Issuer
Holder: Kathleen Caruso (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
+100,000 vol |
100,000 | |
| Filed 2018-03-05 Tx date 2014-07-24 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Frankham, Patrick Charles
4 - Director of Issuer
Holder: Kathleen Caruso (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-03-01 Tx date 2018-02-26 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
+20,000 vol |
20,279,501 | |
| Filed 2018-03-01 Tx date 2018-02-26 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Khadija Zerouali (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
+42,000 vol |
242,000 | |
| Filed 2018-02-28 Tx date 2018-02-27 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
-2,747,252 vol |
||
| Filed 2018-02-28 Tx date 2018-02-28 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
-2,873,562 vol |
17,385,939 | |
| Filed 2018-01-22 Tx date 2018-01-16 |
$PVOT
Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.) |
Doroudian, Ahmad
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Sassel Investments Inc. (Control or Direction)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-240,000
-300,000 vol $0.80 each |
4,464,950 |